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from injury than does inhibition of individual cytokines,
which appear to be produced late and display some functional
redundancy. Selective deletion of the SAPK response in the
lung to oxidative stress could provide protection from pri-
mary graft dysfunction. The exclusive expression of SAPK
in the AM (a resident cell) suggests that pretreatment of po-
tential lung donors could be an effective strategy to limit LIRI
clinically.
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Discussion
Dr David A. Fullerton (Denver, Colo). Dr Wolf, I congratulate you
on both a phenomenal presentation and a really superb article. For
those in the audience who do not think about this on a daily basis,
I would like to point out a couple of things. Number one, there is a tre-
mendous amount of important information in your study. Number
two, the techniques and the model that you have used are quite so-
phisticated, so I think you are to be congratulated again on that point.
I learned a couple of things from your study. One is that it is pos-
sible to—well, let me back up and say what I learned is that MAP
kinases are not uniformly distributed among different tissues, and
so I found one of the novel findings in your study to be the dissoci-
ation of P38 and JNK from ERK1/2 in one organ. Of course, as you
highlighted, P38 and JNK are found in the macrophages, whereas
ERK1/2 are found in the endothelial and epithelial cells. That turns
out to be important, because there is a tremendous amount of interest
in the role of the endothelial and epithelial cells in acute lung injury.
This is of course an important form of acute lung injury, and these
two cell lines have kind of heretofore been ignored in the pathogen-
esis of many of these things.
Could you speculate as to whether your findings suggest that
strategies to effect the response of the endothelial and epithelial cells
are really not very important and that all focus should be on the mac-
rophages? Or perhaps different strategies, other than those you stud-
ied, might be effective in addressing the endothelial and epithelial
cells.
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Dr Wolf. I think that the roles of the endothelial and epithelial
cells in the generation of LIRI are extremely important. Unfortu-
nately, with pharmacologic inhibition in this model, we were not
able to fully suppress ERK1/2 in these cell types because of the col-
lateral effects of higher drug dosing, which would have suppressed
JNK and P38 as well. We are currently starting to examine the role
of targeted molecular deletion in our cell culture model to try and
delineate the cellular signaling mechanisms in response to oxidative
stress within these cell types, and we will try in the future to extrap-
olate these findings to our animal model.
Dr Fullerton. Another question occurred to me. Given the fact
that macrophages are ubiquitous from one organ to the next, and
given the fact that one thing that all solid organ transplants must en-
dure are the injuries of ischemia and reperfusion—and it is thought
of course that macrophages are operative, and I think you have
shown us that in spades—could you speculate a little bit as to
whether not macrophages behave in a similar manner from one or-
gan to the next? For instance, lung versus liver versus heart? Have
your studies addressed any of that?
DrWolf.Our studies did not specifically address the role of mac-
rophages in other organ systems. I think that the Kupffer cell within
the liver probably does have a role similar to that of the AM. They
are both a myeloid-derived lineage. The heart is a little bit tougher to
speculate on, because as far as I know it does not have the same
degree of myeloid-derived cells. I believe that work in one of the
collaborative laboratories at our institution is examining the role
of circulating leukocytes in generating cardiac ischemia–reperfusion
injury.
Unidentified Discussant. I just had one question. It seems that
your model is purely one of warm ischemia. Have you gone further
to simulate a clinical situation of cold ischemia followed by warm
ischemia followed by reperfusion? And have you looked at any of
the readily available pulmonoplegic solutions to see how that affects
the whole injury phenomenon and your model?
DrWolf. Our goal in this study was to recapitulate what we con-
sider the most injurious phase of the reperfusion injury process, the
warm ischemic period. From my understanding with the new pres-
ervation techniques, we can carry cold ischemia out to about 12
hours. In this study we have not done that because as I stated, we
are most interested in the warm ischemic phase.
Dr David Follette (Sacramento, Calif). This was a great study,
beautifully presented and carried out. As Dr Halloran pointed out
and we have looked at, a major component will be the ischemic
injury to the organ, because that affects how the host immune sys-
tem will approach the organ once it is implanted. As Dr Cohen
pointed out, you have a fairly severe model, because in this
whole area there are three components: what happens either
before or during the ischemic phase, the storage phase, and then
the reperfusion phase. My colleague and our member Dr Ardehali
showed how modification of lung reperfusion can make significant
differences.
Are there ways that this knowledge, which is fantastic, can be
applied before the ischemic phase to give added protection against
ischemia, looking more as you have done at a more molecular
way rather than a global way as we would do with either cardiople-
gia or pulmonoplegia?
Dr Wolf. Unfortunately, I do not think that these specific inhib-
itors would lend themselves to the clinical setting, because they lose
specificity at higher doses. We have recently begun to use short
interfering RNA, which we have found localized exclusively to
the AM within the lung. I think that potentially in the future, if we
can reliably continue to show promise, this technique could provide
clinical benefits. This technology is still in its infancy, however, so
we will have to see where this goes.
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